An observational study in Acute Ischemic Stroke (AIS), sponsored by Penumbra Inc.. Recruiting at 12 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Penumbra Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ischemic Stroke by Penumbra Inc. — 2 open to participants now, 2 under way, none of them phase 3. Ischemic Stroke · Penumbra Inc..
Among the 14 studies in Ischemic Stroke by Penumbra Inc., this one is the only one that started in 2025, is one of 9 observational ones, and was the 13th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →2 of the 14 studies in Ischemic Stroke by Penumbra Inc. are open now, in 6 countries. Recruiting first, the newest first:
Penumbra Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 200 is below the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 146 across the 5 interventional studies, 204 across the 9 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Penumbra Inc. is the lead sponsor of 33 studies on the registry; 4 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Ischemic Stroke by Penumbra Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
Post-market, real-world, prospective, single-arm, multi-center study that will enroll up to 200 participants at up to 15 sites globally
Patients presenting with acute ischemic stroke (AIS) who are eligible for aspiration based mechanical thrombectomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Penumbra System®
Device: Penumbra System ®
Neurovacular Mechanical Thrombectomy with the Penumbra System®
Outcomes:
Angiographic revascularization of the occluded target vessel immediately post- procedure as defined by modified Thrombolysis in Cerebral Infarction (mTICI) 2b or higher Angiographic revascularization of the occluded target vessel immediately post- procedure as defined by mTICI 2c or higher * Angiographic revascularization of the occluded target vessel after the first pass as defined by mTICI 2b or higher * Angiographic revascularization of the occluded target vessel after the first pass as defined by mTICI 2c or higher
Time frame: It is anticipated this study will take approximately 2 years. All participants will be followed for approximately 90-day or to outcome (e.g., withdrawal, death), whichever occurs first.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.
Of 42 industry-sponsored observational studies under Ischemic Stroke, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 26 months is close to that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.